Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 5, 2007, Pages 679-688

  Hill, Andrew ^a   Ruxrungtham, Kiat ^b   Hanvanich, Mattana ^b   Katlama, Christine ^c   Wolf, Eva ^d   Soriano, Vincent ^e   Milinkovic, Ana ^f   Gatell, Jose ^f   Ribera, Esteban ^g  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d MUC Research GmbH and MVZ Karlsplatz   (Germany)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

d4T; HAART; HIV; HIV RNA; Lipoartrophy; Mitochondrial toxicity; Nucleoside analogue; Stavudine

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ANEMIA; AREA UNDER THE CURVE; BODY FAT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERLIPIDEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIPOATROPHY; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; DOSE RESPONSE; DRUG EFFECT; EXPERT WITNESS; HUMAN IMMUNODEFICIENCY VIRUS 1; STATISTICS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPERT TESTIMONY; HIV INFECTIONS; HIV-1; HUMANS; META-ANALYSIS; RNA, VIRAL; STAVUDINE;

EID: 34047193054     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.5.679     Document Type: Review

References (35)

1. GILKS C, CROWLEY S, EKPINI R et al.: The WHO public-health approach to antiretroviral treatment against HIV in resource poor settings. Lancet (2006) 368:505-510.
2. HAMMER SM, SAAG MS, SCHECHTER M et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 296:827-843.
3. IRIBARREN JA, LABARGA P, RUBIO R et al.: Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected adults. Enferm. Infecc. Microbiol. Clin. (2004) 22:564-642.
4. CALMY A, PINOGES L, SZUMILIN E et al.: Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS (2006) 20:1163-1169.
5. FERRADINI L, JEANNIN A, PINOGUES L et al.: Scaling up highly active antiretroviral therapy in the district of Malawi: an effectiveness assessment. Lancet (2006) 367:1335-1342.
6. VAN LETH F, PHANUPHAK P, RUXRUNGTHAM K et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet (2004) 363(9417):1253-1263.
7. SPRUANCE S, PAVIA A, MELLORS J et al.: Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine experienced patients in a randomized, double-blind, controlled trial. Bristol-Myers Stavudine 019 Study Group. Ann. Intern. Med. (1997) 126(5):355-363.
8. SQUIRES KE, GULICK R, TEBAS P et al.: A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS (2000) 14(11):1591-1600.
9. WALMSLEY S, BERNSTEIN B, KING M et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl J. Med. (2002) 346:2039-2046.
10. BARTLETT J, FATH M, DEMASI R et al.: An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS (2006) 20:2051-2064.
11. MOCROFT A, PHILLIPS A, LEDERGERBER B et al.: Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viraemia. AIDS (2006) 20:1141-1150.
12. GALLANT J, STASZEWSKI S, POZNIAK A et al.: Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral naïve patients. JAMA (2004) 292:191-201
13. BROWNE M, MAYER K, CHAFEE S et al.: 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex. J. Inf. Dis. (1993) 167:21-29.
14. PETERSEN E, RAMIREZ-RONDA C, HARDY D et al.: Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J. Inf. Dis. (1995) 171(Suppl. 1):S131-S139.
15. CARR A, MILLER J, LAW M et al.: A syndrome of lipoatrophy, lactic acidaemia and liver disfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS (2000) 14:F25-F32.
16. FALC V, CRESPO M, RIBERA E: Lactic acidosis related to nucleoside therapy in HIV infection. Expert Opin. Pharmacother. (2003) 4:1321-1329.
17. 3. J. Acq. Immuno Sydr. (1999) 22:39-45.
18. ANDERSON R, DUNKLE L, SMALDONE L et al.: Design and implementation of the stavudine parallel track programme. Comparison of safety and efficacy of two doses of stavudine in a simple trial in the US parallel track programme. J. Inf. Dis. (1995) 171:118-122.
19. RUXRUNGTHAM K, KROON E, UNGSEDHAPAND C et al.: A randomised, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naïve, HIV-infected Thai patients. AIDS (2000) 14:1375-1382.
20. SIANGPHOE U, SRIKAEW S, WAIWAVARAVUTH C et al.: Efficacy and safety of half dose compared to full dose stavudine (d4T) and zidovudine (AZT) in combination with didanosine (ddI) in Thai HIV infected patients: 96-week results of ACTT002/ARV065 study. World AIDS Conference. Bangkok, Thailand (July 2004) Abstr. WePeB5952.
21. RIBERA E, PARADINERO J, DOMINGO P et al.: A randomized study comparing the efficacy and tolerability of low-dose versus standard-dose stavudine in antiretroviral-naïve patients (ETOX study). 3rd International Conference on AIDS Pathogenesis. Rio de Janiero, Brazil (July 2005) Abstr. TuPe2.4c10.
22. MILINKOVIC A, LOPEZ S, VIDAL S et al.: A randomized open study comparing the effect of reducing stavudine dose versus switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in hiv-infected patients receiving antiretroviral therapy containing stavudine. 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (February 2005) Abstr. 857.
23. SANCHEZ-CONDE M, SORIANO V, GONZALEZ-LAHOZ J: Dose reduction in stavudine from 40 to 30 mg bid provides similar virological and immunological benefit. XV International AIDS Conference (2004) Poster exhibition. Abstr. TuPeB4459.
24. KOEGL C, WOLF E, POSTEL N et al.: Low dose stavudine: as effective as standard dose but less side effects. 9th European AIDS Conference (SACS). Warsaw (25 October 2003) Abstr. 9.8/5.
25. URBINA A, JIBILIAN A, NIBBE Y et al.: Evaluation of viral efficacy and safety of a reduced dose of stavudine (d4T): the PHOENIX study. European AIDS Treatment conference. Dublin, Ireland, (November 2005) Abstr.
26. SHALIT P, FARRELL P, MCCARTHY M: Long-term efficacy of a protease inhibitor sparing, NRTI limiting antiretroviral regimen with nevirapine, lamivudine and reduced dose stavudine dosage. HIV Clin. Trials (2004) 51:62-64.
27. AIT MOHAND H, BONMARCHAND M, GUIGET M et al.: Evaluation of viral efficacy and safety of a reduced dose of stavudine (d4T): the PHOENIX study. European AIDS Treatment Conference. Dublin, Ireland, (November 2005) Abstr.
28. HANVANICH M, PRASANTHAI V, RIENGCHAN P et al.: Reduction of d4T dosage improves lipoatrophy without virologic failure. Antiviral Therapy (2003) 8(Suppl. 1): S392 Abstr. 749.
29. DELPIERRE C, CUZIN L, ALVAREZ M et al.: Lowering stavudine dosages does not compromise anti-viral efficacy in HIV-1 infected patients. IAS Conference on pathogenesis Rio de Janiero, Brazil (July 2005) Abstr.
30. ARMITAGE P, BERRYG: Statistical Methods in Medical Research, 3rd edn. Blackwell Scientific Publications, Oxford, UK (1994).
31. CROSS J, LEE H, WESTELINK A et al.: Postmarketing drug dosage changes of 499 FDA approved new molecular entities. Pharmaco Drug Safety (2002) 11:439-446.
32. MOYLE G, SABIN C, CARTLEDGE J et al.: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipodystrophy. AIDS (2006) 20:2043-2050.
33. BOULASSEL M, MORALES R, MURPHY T et al.: Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected patients. J. Med. Virol. (2006) 78:1158-1163.
34. CALMY A, PINOGUES L, SZUMILIN E et al.: Scaling up highly active antiretroviral therapy in the district of Malawi: an effectiveness assessment. Lancet (2006) 367:1335-1342.
35. FERRADINI L, JEANNIN A, PINOGUES L et al.: Scaling up highly active antiretroviral therapy in the district of Malawi: an effectiveness assessment. Lancet (2006) 367:1335-1342.